Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$-145.62 Mln
EBITDA
$-183.77 Mln
Net Profit
$-176.64 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fresh Tracks Therapeutics Inc (FRTX)
| -- | -- | -- | 3.8 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2023
|
|---|---|
|
Fresh Tracks Therapeutics Inc (FRTX)
| -41.3 |
|
BSE Sensex
| 18.7 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the... United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. Read more
CEO, CFO, Secretary & Chairman
Mr. Albert Nicholas Marchio II
CEO, CFO, Secretary & Chairman
Mr. Albert Nicholas Marchio II
Headquarters
Boulder, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Fresh Tracks Therapeutics Inc (FRTX) is $0.94 (NASDAQ) as of 28-Feb-2025 12:19 EDT. Fresh Tracks Therapeutics Inc (FRTX) has given a return of 3.77% in the last 1 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.91
|
0.52
|
|
2022
|
-0.22
|
0.63
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Fresh Tracks Therapeutics Inc (FRTX) are Rs -- and Rs -- as of 04-Apr-2026.
Fresh Tracks Therapeutics Inc (FRTX) has a market capitalisation of $ 6 Mln as on 28-Feb-2025. As per SEBI classification, it is a company.
Before investing in Fresh Tracks Therapeutics Inc (FRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.